British drugmaker GSK plc (NYSE:GSK) is betting on blockbuster potential for its experimental cancer therapy Mo-rez, after early trial data showed the drug shrank tumors in patients with advanced, hard-to-treat gynecological cancers.
“Do we think it would be a blockbuster? Yes, absolutely,” GSK’s head of oncology research, Hesham Abdullah, told reporters on Sunday, as the data was presented at a medical conference in Puerto Rico, according to Reuters.
In platinum-resistant ovarian cancer, 62% of patients achieved at least a 30% reduction in tumor size. In endometrial cancer, 67% met that threshold.
Mo-rez is an antibody-drug conjugate that targets the B7H4 protein found on gynecological cancer cells but largely absent …
This post was originally published here
